Methotrexate for psoriasis: effective, safe, favourable. Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva. Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no […]
Enhancing the potential of methotrexate. Optimise rheumatism treatment with Metoject® and ensure long-term success of therapy Stuttgart / Wedel (September 11, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the CAPEA cohort suggest that German rheumatology exploits the potential of methotrexate […]
Update on the first-line agent Methotrexate in psoriasis treatment: Intensified dosing and subcutaneous administration recommended British Association of Dermatologists’ guidelines reaffirms the importance of the well- established and inexpensive first-line systemic agent Methotrexate (MTX) for the treatment of patients with all types of psoriasis Recently in The Lancet published METOP trial meets the need of […]
/wp-content/uploads/2017/03/logoBlueNew3.png00Admin medac/wp-content/uploads/2017/03/logoBlueNew3.pngAdmin medac2017-07-07 15:08:222019-03-13 15:25:14Press Release - medac at the BAD meeting 2017
medac passes eco-audit and receives award for environmental management medac Gesellschaft für klinische Spezialpräparate mbH is innovative, successful, sustainable and environment-friendly. The pharmaceutical company has proven that economic prosperity and environmental responsibility are not necessarily a contradiction. To achieve perfect conditions for this objective, medac subjected itself to an auditing procedure according to EMAS and […]
Benefits for psoriasis practices: New phase III data shows subcutaneous methotrexate’s favorable long-term efficacy and safety profile. Medac hosted a satellite symposium at the EADV conference 2016 in Vienna with the title METOP study – evaluation of subcutaneous methotrexate for psoriasis patients. Satellite symposium took place on Friday 30th of September, 2016 at Hall L3, floor […]
Press release – Medac at the EADV 2017
/in kategorioimaton /by Admin medacMethotrexate for psoriasis: effective, safe, favourable. Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva. Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no […]
Press release – Medac at DGRh 2017
/in kategorioimaton /by Admin medacEnhancing the potential of methotrexate. Optimise rheumatism treatment with Metoject® and ensure long-term success of therapy Stuttgart / Wedel (September 11, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the CAPEA cohort suggest that German rheumatology exploits the potential of methotrexate […]
Press Release – medac at the BAD meeting 2017
/in kategorioimaton /by Admin medacUpdate on the first-line agent Methotrexate in psoriasis treatment: Intensified dosing and subcutaneous administration recommended British Association of Dermatologists’ guidelines reaffirms the importance of the well- established and inexpensive first-line systemic agent Methotrexate (MTX) for the treatment of patients with all types of psoriasis Recently in The Lancet published METOP trial meets the need of […]
Press Release – medac passes eco-audit
/in kategorioimaton /by Admin medacmedac passes eco-audit and receives award for environmental management medac Gesellschaft für klinische Spezialpräparate mbH is innovative, successful, sustainable and environment-friendly. The pharmaceutical company has proven that economic prosperity and environmental responsibility are not necessarily a contradiction. To achieve perfect conditions for this objective, medac subjected itself to an auditing procedure according to EMAS and […]
EADV 2016 – METOP study in medac satellite symposium
/in kategorioimaton /by Carita KoskinenBenefits for psoriasis practices: New phase III data shows subcutaneous methotrexate’s favorable long-term efficacy and safety profile. Medac hosted a satellite symposium at the EADV conference 2016 in Vienna with the title METOP study – evaluation of subcutaneous methotrexate for psoriasis patients. Satellite symposium took place on Friday 30th of September, 2016 at Hall L3, floor […]